临床试验/NCT04161755

NCT04161755进行中（未招募）1 期

Phase 1 Clinical Trial of Personalized Neoantigen Tumor Vaccines and Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Surgically Resected Pancreatic Cancer

Memorial Sloan Kettering Cancer Center12 个研究点分布在 1 个国家目标入组 29 人开始时间: 2019年12月13日最近更新: 2026年1月7日

适应症

干预措施

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Memorial Sloan Kettering Cancer Center
入组人数: 29
试验地点: 12
主要终点: Drug related toxicity

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验相关资讯

研究概览

简要总结

The purpose of this study is to evaluate the safety or treating pancreatic cancer with surgery to remove cancerour tissue, followed by atezolizumab, followed by a personalized cancer vaccine (PCV), and then with chemotherapy.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Subjects must be >/= 18 years of age at time of informed consent
•Able to comply with the study protocol, in the investigator's judgment
•Subjective with radiographically resectable primary pancreatic tumors with radiographic features consistent with adenocarcinoma will be evaluated for surgical resection
•Tumors must be radiographically resectable, defined as:
•A clear fat plane around the celiac and superior mesenteric arteries
•patent superior mesenteric and portal veins without primary tumor involvement
•No encasement of the superior mesenteric vein or portal veins
•No encasement of the superior mesenteric or hepatic arteries
•No metastatic disease
•No extra-regional nodal disease
•Subjects with histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1) will be selected for neoantigen vaccine creation. Subjects with neuroendocrine (and mixed type) tumors are excluded
•Pancreatic cancer surgical staging: T 1-3, N0-2, M0
•° Per AJCC 8th edition staging
•Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) Scale of Performance Status (Section 20.0 APPENDICES, Appendix1)
•Subjects must not have had prior chemotherapy, radiation therapy, or immunotherapy for PDAC
•Subjects must be able to read, understand, and sign informed consent
•Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to study initiation
•For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures that result in a failure rate of less than (<) 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab and for at least 90 days after the last dose of RO
•A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (>/= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus)
•For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom during the entire study period and up to 90 days after last administration of RO
•Male participants should not donate sperm for 90 days after the last dose of RO7198457
•Examples of contraceptive methods with a failure rate of <1% per year include bilateral tubal ligation, male sterilization and established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices and copper intrauterine devices
•Hormonal contraceptive methods must be supplemented by a barrier method plus spermicide
•The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception

排除标准

•A subject will not be eligible for inclusion in this study if any of the following criteria apply:
•Prior neoadjuvant treatment or radiation therapy for PDAC
•Prior therapy with uPD-1 antibody or any other immune therapy
•Borderline resectable, locally unresectable or metastatic PDAC
•Pancreas tumor histology other than PDAC
•Pregnancy, breastfeeding, or intending to become pregnant during the study or within 90 days after the last dose of study treatment
•Life expectancy less than 12 weeks
•Inability to comply with study and/or follow-up procedures
•Any other malignancy for which the patient is undergoing active treatment which will be concurrent with the investigational agent in this study.
•Patients with unresolved Clavien-Dindo >/= Grade 3 (Section 20.0 APPENDICES ,Appendix 2) postoperative complications
•Actie, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment
•Active tuberculosis
•Known infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection or subjects receiving immunosuppressive or myelosuppressive medications that would, in the opinion of the investigator, increase the risk of serious neutropenic complications
•Known hypersensitivity or allergy to the active substance or to any of the excipients of RO7198457, atezolizumab, oxaliplatin, leucovorin, irinotecan, or fluorouracil
•Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the subject's safety or the study data integrity. These include, but are not limited to:
•History of connective tissue disorders (e.g., lupus, scleroderma, arteritis nodosa)
•History of interstitial lung disease, slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, or multiple allergies
•History of the following within 6 months prior to RO7198457 administration: a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) Class III-IV heart failure, uncontrolled hypertension, clinically significant cardiac dysthythmia, or electrocardiogram (ECG) abnormality (exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia), cerebrovascular accident, transient ischemic attack,, or seizure disorder
•History or autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis with the following caveats:
•Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible
•Patient with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible
•Patients type 2 diabetes mellitus may be eligible
•° Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., no psoriatic arthritis) may be eligible provided that they meet the following conditions:
•Rash must cover less than 10% of the body surface area (BSA)
•Disease is well controlled at baseline and only requires low potency topical steroids
•No acute exacerbations of underlying condition within the last 12 months (e.g., not requiring psorlen and ultraviolet A (PUVA) radiation, methotrexate retinoids, biologic agents, oral calcineurin inhibitors, high potency, or oral steroids)
•Treatment with systemic immunosuppressive medication (including but not limited to prednisone >10mg/day, cyclophosphamide, azathioprine, methotrexate, thalidomide, and TNF-x antagonists) within 2 weeks prior to RO7198457 administration. Patients who have received acute, low-dose, systemic immunosuppressant medication (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study after discussion with and approval by the PI and Co-PI. The use of inhaled corticosteroids (e.g., fluticasone for chronic obstructive pulmonary disease) is allowed. The use of oral mineralocorticoids (e.g., flurocortisone for patients with orthostatic hypotension) is allowed. Physiologic doses of corticosteroids for adrenal insufficiency are allowed.
•Subjects with allergies to IV contrast agents requiring pretreatment with corticosteroids will be excluded. Corticosteroids are immunosuppressive and may interfere with RO7198457 tolerability and efficacy. Given that there are serial contrast agent-dependent follow-up imaging studies built into the study which will overlap with vaccination, subjects who require pretreatment with corticosteroids prior to IV contrast administration will be excluded
•History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchioloitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted
•Known primary immunodeficiencies, either cellular (e.g., DiGeorge syndrome, T-negative severe combined immunodeficiency [SCID]) or combined T- and B-cell immunodeficiencies (e.g., T- and B-negative SCID, Wiskott-Aldrich syndrome, ataxia telangiectasia, common variable immunodeficiency)
•Prior allogeneic bone marrow transplantation or prior solid organ transplantation
•Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug
•Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, and inherited liver disease or current alcohol abuse
•Previous splenectomy
•Administration of a live, attenuated vaccine within 4 weeks before RO7198457 administration or anticipation that such a live attenuated vaccine will be required during the study. Influenza vaccination should be given during influenza season only. Patients must not receive live, attenuated influenza vaccine (e.g., FluMist) within 4 weeks prior to RO7198457 administration or at any time during the study, and for 90 days following the last study treatment

研究组 & 干预措施

Pancreatic Cancer

Experimental

Radiologically resectable primary pancreatic tumors

干预措施: Atezolizumab (Drug)

Pancreatic Cancer

Experimental

Radiologically resectable primary pancreatic tumors

干预措施: RO7198457 (Biological)

Pancreatic Cancer

Experimental

Radiologically resectable primary pancreatic tumors

干预措施: mFOLFIRINOX (Drug)

结局指标

主要结局

Drug related toxicity

时间窗: 2 years

The primary objective of this trial is to evaluate the safety of a personalized tumor vaccine combined with atezolizumab and mFOLFIRINOX

次要结局

未报告次要终点

研究者

发起方

Memorial Sloan Kettering Cancer Center

申办方类型

Other

责任方

Sponsor

研究点 (12)

Loading locations...

相似试验

已完成

1 期

Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to SurgeryPancreas CancerCancer of the PancreasPancreatic Cancer

NCT05111353Washington University School of Medicine33

已完成

1 期

Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic CancerPancreatic CarcinomaPancreatic Cancer

NCT03645148Zhejiang Provincial People's Hospital7

招募中

1 期

Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant ChemotherapyResectable Pancreatic Cancer

NCT04810910Zhejiang Provincial People's Hospital20

进行中（未招募）

1 期

A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma

NCT05846516Boehringer Ingelheim59

招募中

早期 1 期

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic CancerPancreatic Cancer

NCT06326736Jinling Hospital, China12